What is the CVSS score of CVE-2026-47946?

CVE-2026-47946 has a CVSS 3.1 base score of 5.4 (Medium). CVSS vector: CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:N. EPSS exploitation probability: 0.0%.

Adobe Experience Manager CVE-2026-47946

EUVD-2026-35719 MEDIUM

Cross-site Scripting (XSS) (CWE-79)

2026-06-09 psirt@adobe.com

GHSA-67jr-5ggx-cm8x

XSS Adobe Experience Manager

5.4

CVSS 3.1 · Vendor: adobe

Severity by source

Vendor (adobe) PRIMARY

5.4 MEDIUM

AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:N

Primary rating from Vendor (adobe) · only source for this CVE.

CVSS VectorVendor: adobe

Attack Vector

Network

Attack Complexity

Low

Privileges Required

Low

User Interaction

Required

Scope

Changed

Confidentiality

Low

Integrity

Low

Availability

None

Lifecycle Timeline

Analysis Generated

Jun 09, 2026 - 19:29 vuln.today

DescriptionCVE.org

Adobe Experience Manager versions 6.5.24, LTS SP1, 2026.04 and earlier are affected by a DOM-based Cross-Site Scripting (XSS) vulnerability. An attacker could exploit this issue by manipulating the DOM environment to execute malicious JavaScript within the context of the victim's browser. Exploitation of this issue requires user interaction in that a victim must visit a crafted webpage. Scope is changed.

AnalysisAI

DOM-based Cross-Site Scripting in Adobe Experience Manager (AEM) versions 6.5.24, LTS SP1, and 2026.04 and earlier allows an authenticated attacker to inject and execute malicious JavaScript within a victim's browser by manipulating the Document Object Model. The CVSS Scope:Changed rating signals that successful exploitation breaks out of the vulnerable component's security boundary, enabling impact on resources beyond AEM itself - such as adjacent browser sessions or stored credentials. No public exploit identified at time of analysis, and CISA KEV listing is absent, but the low attack complexity and changed scope make this a meaningful risk for organizations running AEM with untrusted low-privilege users.

Technical ContextAI

DOM-based XSS (CWE-79) is distinct from reflected or stored XSS in that the vulnerability exists entirely in client-side JavaScript logic: attacker-controlled data is written into the DOM and then read and executed by other client-side scripts without adequate sanitization, without the server ever seeing or reflecting the malicious payload. The affected product is Adobe Experience Manager - a Java/OSGi-based enterprise CMS - across the 6.5.x LTS branch (up to 6.5.24 and LTS SP1) and the cloud-native 2026.04 release and earlier. The CVSS vector AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:N characterizes a network-reachable, low-complexity attack requiring only low privileges, user interaction, with scope change and limited confidentiality/integrity impact. The scope change (S:C) is technically significant: it indicates the injected script operates in a security context different from the vulnerable AEM component, consistent with script execution affecting the broader browser origin.

RemediationAI

Consult and apply the guidance in Adobe Security Bulletin APSB26-56 at https://helpx.adobe.com/security/products/experience-manager/apsb26-56.html - this is the authoritative source for exact patched versions across both the 6.5.x LTS and 2026.x cloud release tracks. The exact fixed version numbers are not independently confirmable from the available intelligence data and must be retrieved directly from APSB26-56. As a compensating control pending patching, restrict AEM Author environment access to trusted internal networks and authenticated users only, reducing the attacker's ability to deliver a crafted payload to a privileged victim. Disabling or filtering HTML/JavaScript input in AEM authoring components may reduce attack surface but can break legitimate content-authoring workflows and should be evaluated carefully. Content Security Policy (CSP) headers on AEM-served pages can limit the damage of injected scripts by restricting script sources and preventing exfiltration to attacker-controlled domains - a viable defense-in-depth measure with low operational side-effects.